HomeCompareACER vs GBDC

ACER vs GBDC: Dividend Comparison 2026

ACER yields 302.98% · GBDC yields 11.86%● Live data

vsPost on X →
After 10 years · $10,000 invested · DRIP enabled
🏆 ACER wins by $1597.49M in total portfolio value
10 years
ACER
ACER
● Live price
302.98%
Share price
$0.66
Annual div
$2.00
5Y div CAGR
0%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$1618.34M
Annual income
$981,251,733.53
Full ACER calculator →
GBDC
GBDC
● Live price
11.86%
Share price
$12.65
Annual div
$1.50
5Y div CAGR
51.1%
Payout ratio
50%
After 10 yrs · $10,000 · DRIP
Portfolio value
$20.85M
Annual income
$16,450,733.83
Full GBDC calculator →

Portfolio growth — ACER vs GBDC

📍 ACER pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis PeriodACERGBDC
2008–2009
GFC
— No data— No data
2020 Q1–Q2
COVID
— No data— No data
2022 Q4
Rate Hike
— No data— No data
Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.
📅

Dividend Calendar Overlap

Combined, ACER + GBDC cover 0 of 12 monthsgood coverage

Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
ACER pays
GBDC pays
Both pay
Neither
💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

ACER
Annual income on $10K today (after 15% tax)
$25,753.67/yr
After 10yr DRIP, annual income (after tax)
$834,063,973.50/yr
GBDC
Annual income on $10K today (after 15% tax)
$1,007.91/yr
After 10yr DRIP, annual income (after tax)
$13,983,123.76/yr
At 15% tax rate, ACER beats the other by $820,080,849.75/year in after-tax income after 10 years on $10,000
⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of ACER + GBDC for your $10,000?

ACER: 50%GBDC: 50%
100% GBDC50/50100% ACER
Portfolio after 10yr
$819.59M
Annual income
$498,851,233.69/yr
Blended yield
60.87%
📊

Analyst Conviction Gap

Where Wall Street is most bullish on GBDC right now

ACER
Analyst Ratings
1
Strong
3
Buy
4
Hold
Consensus: Hold
Altman Z
-29.9
Piotroski
4/9
GBDC
Analyst Ratings
6
Buy
5
Hold
Consensus: Buy
Price Target
$14.00
+10.7% upside vs current
Range: $13.00 — $15.00
Altman Z
0.6
Piotroski
6/9
Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.
🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

ACER buys
0
GBDC buys
0
No recent congressional trades found for ACER or GBDC in the last 90 days.
STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →
MetricACERGBDC
Forward yield302.98%11.86%
Annual dividend / share$2.00$1.50
Payout ratio50%50%
1-year div growth0%0%
5-year div CAGR0%51.1%
Portfolio after 10y$1618.34M$20.85M
Annual income after 10y$981,251,733.53$16,450,733.83
Total dividends collected$1554.65M$20.43M
Payment frequencyquarterlyquarterly
SectorStockBDC
Analyst consensusHoldBuy

Year-by-year: ACER vs GBDC ($10,000, DRIP)

YearACER PortfolioACER Income/yrGBDC PortfolioGBDC Income/yrGap
1← crossover$40,998$30,298.44$12,492$1,791.70+$28.5KACER
2$159,961$116,092.41$16,527$3,160.58+$143.4KACER
3$594,475$423,317.38$23,588$5,904.90+$570.9KACER
4$2,106,378$1,470,289.30$37,141$11,901.65+$2.07MACER
5$7,122,619$4,868,794.58$66,205$26,463.38+$7.06MACER
6$23,007,746$15,386,544.17$137,452$66,612.65+$22.87MACER
7$71,068,926$46,450,637.66$342,372$195,298.53+$70.73MACER
8$210,139,057$134,095,305.48$1,053,292$686,954.33+$209.09MACER
9$595,407,325$370,558,534.30$4,111,439$2,984,416.95+$591.30MACER
10$1,618,337,571$981,251,733.53$20,849,974$16,450,733.83+$1597.49MACER

ACER vs GBDC: Complete Analysis 2026

ACERStock

Acer Therapeutics Inc., a pharmaceutical company, focuses on the acquisition, development, and commercialization of therapies for serious rare and life-threatening diseases. Its pipeline includes four clinical-stage candidates comprising EDSIVO for the treatment of vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a formulation of sodium phenylbutyrate for the treatment of various inborn errors of metabolism, including urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant) for the treatment of induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy against a variety of infectious diseases, including COVID-19. The company has a research collaboration agreement with the National Center for Advancing Translational Sciences (NCATS) to develop emetine hydrochloride as a potential treatment for patients with COVID-19; and a license agreement with Sanofi to acquire worldwide rights to osanetant, a clinical-stage, selective, and non-peptide tachykinin NK3 receptor antagonist. Acer Therapeutics Inc. was incorporated in 1991 and is headquartered in Newton, Massachusetts.

Full ACER Calculator →

GBDCBDC

Golub Capital BDC, Inc. (GBDC) is a business development company and operates as an externally managed closed-end non-diversified management investment company. It invests in debt and minority equity investments in middle-market companies that are, in most cases, sponsored by private equity investors. It typically invests in diversified consumer services, automobiles, healthcare technology, insurance, health care equipment and supplies, hotels, restaurants and leisure, healthcare providers and services, IT services and specialty retails. It seeks to invest in the United States. It primarily invests in first lien traditional senior debt, first lien one stop, junior debt and equity, senior secured, one stop, unitranche, second lien, subordinated and mezzanine loans of middle-market companies, and warrants.

Full GBDC Calculator →
📬

Get this ACER vs GBDC comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

ACER vs SCHDACER vs JEPIACER vs OACER vs KOACER vs MAIN

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.